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A B S T R A C T
Purpose
Philadelphia chromosome (Ph) –like acute lymphoblastic leukemia (ALL) is a high-risk subtype of
childhood ALL characterized by kinase-activating alterations that are amenable to treatment with
tyrosine kinase inhibitors.We sought to deﬁne the prevalence and genomic landscape of Ph-like ALL
in adults and assess response to conventional chemotherapy.
Patients and Methods
The frequency of Ph-like ALL was assessed by gene expression proﬁling of 798 patients with B-cell
ALL age 21 to 86 years. Event-free survival and overall survival were determined for Ph-like ALL
versus non–Ph-like ALL patients. Detailed genomic analysis was performed on 180 of 194 patients
with Ph-like ALL.
Results
Patients with Ph-like ALL accounted for more than 20% of adults with ALL, including 27.9% of
young adults (age 21 to 39 years), 20.4% of adults (age 40 to 59 years), and 24.0% of older adults
(age 60 to 86 years). Overall, patients with Ph-like ALL had an inferior 5-year event-free survival
compared with patients with non–Ph-like ALL (22.5% [95% CI, 14.9% to 29.3%; n = 155] v 49.3%
[95% CI, 42.8% to 56.2%; n = 247], respectively; P , .001). We identiﬁed kinase-activating al-
terations in 88% of patients with Ph-like ALL, including CRLF2 rearrangements (51%), ABL class
fusions (9.8%), JAK2 or EPOR rearrangements (12.4%), other JAK-STAT sequence mutations
(7.2%), other kinase alterations (4.1%), and Ras pathway mutations (3.6%). Eleven new kinase
rearrangements were identiﬁed, including four involving new kinase or cytokine receptor genes and
seven involving new partners for previously identiﬁed genes.
Conclusion
Ph-like ALL is a highly prevalent subtype of ALL in adults and is associated with poor outcome. The
diverse range of kinase-activating alterations in Ph-like ALL has important therapeutic implications.
Trials comparing the addition of tyrosine kinase inhibitors to conventional therapy are required to
evaluate the clinical utility of these agents in the treatment of Ph-like ALL.
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INTRODUCTION
Despite remarkable improvements in the treat-
ment outcome for children with acute lympho-
blastic leukemia (ALL),1 the prognosis of adults
with ALL is poor, with 5-year survival rates of
40% overall2 and approximately 7% for patients
who experience relapse.3 Current chemotherapy
regimens are limited in adults as a result of
toxicity. Compared with children, adult patients
with ALL have an increased frequency of high-risk
genetic alterations, such as BCR-ABL1, IGH, or
MLL rearrangements, and complex karyotypes.4,5
However, the genetic basis of adult ALL is in-
completely understood.
Philadelphia chromosome (Ph) –like or
BCR-ABL1–like ALL6,7 is a high-risk subtype of
ALL characterized by rearrangements, sequence
mutations, and copy number alterations involv-
ing kinase or cytokine receptor genes.8,9 The
prevalence of Ph-like ALL increases from 10% in
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standard-risk childhood ALL to more than 25% in young adults.8
Preclinical studies and case reports indicate that the addition of
tyrosine kinase inhibitors (TKIs) to current chemotherapeutic
regimens may improve the poor outcome of patients with Ph-like
ALL.10-13
The prevalence of Ph-like ALL in adults is unclear. A recent
report from the Dutch-Belgium Hemato-Oncology Cooperative
Group identiﬁed Ph-like ALL in 17% of patients age 16 to 71
years.14 Another report from the German Multicenter ALL group
observed a peak prevalence of Ph-like ALL of approximately 20%
in adolescents and young adults, which decreased to less than
10% in adults age 40 to 84 years.15 Both studies examined small
numbers of patients, used different methods for identifying the Ph-
like ALL gene signature, and lacked genomic characterization. A
comprehensive understanding of the prevalence, outcome, and
genetic basis of Ph-like ALL in adults is needed to identify patients
who may beneﬁt from TKI therapy and to determine the optimal
TKIs to use. Here, we demonstrate that the incidence of Ph-like
ALL exceeds 20% in patients age 21 to 86 years at diagnosis, is
associated with a poor outcome, and is composed of genetic al-
terations that activate tyrosine kinase or cytokine receptor sig-
naling. These results suggest that the identiﬁcation of patients with
Ph-like ALL should be incorporated into the design of future
clinical trials.
PATIENTS AND METHODS
Patients and Treatment
We studied leukemia samples from banked material obtained at
diagnosis from 909 patients with precursor B-cell ALL (B-ALL), 798 of
whom had suitable material for genomic analysis (Appendix Fig A1, online
only). Patients were enrolled onto clinical trial protocols of the following
groups or centers: Alliance for Clinical Trials in Oncology Group (Cancer
and Leukemia Group B) protocols C19802 (ClinicalTrials.gov identiﬁer:
NCT00003700),16 C10102 (NCT00061945), and C10403 (NCT00558519);
the Eastern Cooperative Oncology Group–American College of Radi-
ology Imaging Network protocols E29932 (NCT00002514) and E1910
(NCT02003222); The University of Texas MD Anderson Cancer Center
(MDACC)17-20; Northern Italy Leukemia Group protocols 09-200021 and 10/
07 (NCT00795756); Princess Margaret Cancer Centre22; Southwest Oncology
Group protocols S0333 (NCT00109837) and S9400 (NCT00002665)23; and
City of Hope. The cohort was divided into the following three age groups:
young adults (n = 344; age 21 to 39 years), adults (n = 304; age 40 to 59
years), and older adults (n = 150; age 60 to 86 years; Table 1; Data
Supplement). Details for patient samples are provided in the Data Sup-
plement. Patients gave written informed consent for sample collection and
research. The study was approved by the St Jude Institutional Review
Board.
Genomic Profiling
Gene expression proﬁling was performed at the University of New
Mexico Cancer Center on 798 RNA samples using either U133 Plus 2.0
microarrays (Affymetrix, Santa Clara, CA)8 or a 15-gene Taqman (Thermo
Fisher, Waltham, MA) quantitative reverse transcriptase polymerase chain
reaction (PCR) low-density array (LDA) that identiﬁes the Ph-like ALL
gene signature, P2RY8-CRLF2, BCR-ABL1, ETV6-ABL1, TCF3-PBX1, and
DUX4/ERG-deregulated ALL (Data Supplement).24 Analysis of the 15
genes results in an integrated value between 0 and 1, termed the Ph-like
coefﬁcient. Patients with a coefﬁcient of 0.5 to 1 were designated as having
Ph-like ALL. All other genomic assays were performed at St Jude Children’s
Research Hospital (Memphis, TN). High expression of CRLF2 was de-
termined by the LDA card, and CRLF2 rearrangements (IGH-CRLF2 or
P2RY8-CFRLF2) were conﬁrmed using ﬂuorescence in situ hybridization
(FISH) as described in the Data Supplement. PCR and Sanger sequencing
of tumor cDNAwas performed to detect sequence mutations in JAK1 and
JAK2 (Data Supplement). A ﬂowchart outlining the genomic assays
performed is provided in the Data Supplement. Single nucleotide poly-
morphism (SNP) analysis was performed on 165 of 194 Ph-like samples
with available DNA using either SNP 6.0 microarrays (Affymetrix; n = 49)
or the InﬁniumOmni2.5Exome-8 BeadChip Kit (Illumina, San Diego, CA;
n = 116). Details for the LDA algorithm and SNP processing are provided
in the Data Supplement.
Transcriptome Sequencing
Transcriptome sequencing (RNA-seq) was performed using the
TruSeq library preparation on the Illumina HISeq 2000 platform. All
sequencing was paired end and performed using either total RNA and
stranded RNA sequencing (n = 63) or polyadenylated-selected non-
stranded sequencing (n = 23).8 Sequencing metrics and processing
details are provided in the Data Supplement. Samples were analyzed by
CICERO8 and FusionCatcher25 to detect fusions. Sequence mutations
were analyzed from RNA-seq according to the Genome Analysis Toolkit
pipeline.26
Table 1. Clinical Characteristics of All Patients
Characteristic Young Adult Patients (n = 344)
Adult Patients
(n = 304) Older Adult Patients (n = 150)
All Patients
(N = 798)
Median age, years (range) 28 (21-39) 48 (40-59) 66 (60-86) 42 (21-86)
Median WBC count, 3 109/L (range) 61.1 (0.4-658) 48.7 (0.2-588) 53.2 (0.7-670) 54.8 (0.2-670)
Sex, No. (%)
Male 194 (56.4) 135 (44.0) 71 (47.3) 400 (50.1)
Female 148 (43.0) 169 (56.0) 78 (52.0) 395 (49.5)
Unknown 2 (0.6) 0 (0) 1 (0.7) 3 (0.4)
Genomic subtype, No. (%)
BCR-ABL1 66 (19.2) 73 (24.0) 46 (30.7) 185 (23.2)
Philadelphia chromosome–like 96 (27.9) 62 (20.4) 36 (24.0) 194 (24.3)
MLL 51 (14.8) 52 (17.1) 20 (13.3) 123 (15.4)
ETV6-RUNX1 7 (2.0) 1 (0.3) 0 (0) 8 (1.0)
TCF3-PBX1 10 (2.9) 12 (3.9) 1 (0.7) 23 (2.9)
DUX4/ERG 11 (3.2) 7 (2.3) 0 (0) 18 (2.3)
B-cell other 103 (29.7) 97 (31.9) 47 (31.3) 247 (31.0)
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Statistical Analysis
Associations between categorical values were examined using Fisher’s
exact test. Event-free survival and overall survival from diagnosis were
estimated using the Kaplan-Meier method. All groups were compared
using the log-rank test.27 An event was deﬁned as a failure to achieve
remission, a relapse after remission, or the development of a second
malignancy. A multivariable analysis of event-free and overall survival was
performed using the Cox proportional hazards regression model.28 An-
alyses were performed using Prism software version 6.0 (GraphPad
Software, La Jolla, CA), R software (www.r-project.org), and SAS software
version 9.1.2 (SAS Institute, Cary, NC).
RESULTS
Clinical Characteristics
Overall, 194 (24.3%) of 798 patients with B-ALL were clas-
siﬁed as having Ph-like ALL. The prevalence of ETV6-RUNX1,
TCF3-PBX1, and DUX4/ERG ALLwas low (1.0%, 2.9%, and 2.3%,
respectively), whereas the prevalence of patients with BCR-ABL1
and MLL-rearranged ALL was 23.2% and 15.4%, respectively. The
prevalence of Ph-like ALL exceeded 20% in all age groups (27.9%
in young adults, 20.4% in adults, and 24.0% in older adults;
Table 1; Data Supplement). Patients with Ph-like ALL had higher
WBC counts at diagnosis compared with patients with non–Ph-
like ALL (excluding BCR-ABL1 andMLL), both overall (mean, 56.6
v 26.8 3 109/L, respectively; P , .001) and in the different age
cohorts (Table 2; Data Supplement). A higher proportion of pa-
tients with Ph-like ALL were male compared with patients with
non–Ph-like ALL (61.3% v 50%, respectively; P = .0094; Table 2).
Treatment Outcomes
Among all patients, increasing age was associated with inferior
outcome. The 5-year event-free survival rates for young adults,
adults, and older adults were 40.4% (95% CI, 34.1% to 46.8%),
29.8% (95% CI, 23.3% to 36.0%), and 18.9% (95% CI, 8.9% to
27.1%; P, .001), respectively, with 5-year overall survival rates of
45.2% (95% CI, 38.8% to 51.9%), 35.1% (95% CI, 28.4% to
41.8%), and 16.2% (95% CI, 4.7% to 24.8%; P , .001; Fig 1),
respectively. Overall, the outcome of patients with Ph-like ALLwas
inferior compared with the outcome of patients with non–Ph-like
ALL (excluding BCR-ABL1 and MLL), with 5-year event-free
survival rates of 22.5% (95% CI, 14.9% to 29.3%) compared
with 49.3% (95% CI, 42.8% to 56.2%; P , .001) and overall
survival rates of 23.8% (95% CI, 16.0% to 32.4%) compared with
52.4% (95% CI, 45.4% to 59.9%; P , .001; Fig 2 and Data
Supplement), respectively. In multivariable analyses, age (hazard
ratio [HR], 2.55; P , .001), sex (HR, 1.97; P , .001), and the
presence of Ph-like ALL (HR, 1.48; P = .014) were independently
associated with poor survival (Data Supplement). Minimal residual
disease at the end of induction was assessed by six-color ﬂow
cytometry for patients treated on The University of Texas MD
Anderson Cancer Center protocols. Of those tested, patients
with Ph-like ALL were less likely to achieve minimal residual
disease–negative remission (, 0.01% minimal residual disease)
compared with patients with non–Ph-like ALL (47% [n = 19] v
94% [n = 17], respectively; P = .002). Outcome after hemato-
poietic stem-cell transplantation was available for patients enrolled
onto E2993. There was no signiﬁcant difference in survival be-
tween patients who did (n = 7) and did not receive transplantation
(n = 14; P = .2; Data Supplement).
Inferior outcome was observed for patients with Ph-like ALL
compared with patients with non–Ph-like ALL among young
adults and adults, with 5-year event-free survival rates of 24.1%
(95% CI, 12.6% to 34.1%) compared with 60.5% (95% CI, 51.2%
to 71.4%; P , .001) and 21.4% (95% CI, 7.6% to 32.5%) com-
pared with 38.7% (95% CI, 27.6% to 50.0%; P = .0021; Data
Supplement), respectively. The difference in outcomes was not
signiﬁcant for older adults, with 3-year event-free survival rates of
8.0% (95% CI, 0.5% to 21.6%) and 33.3% (95% CI, 15.8% to
52.2%; P = .47) for patients with Ph-like ALL and non–Ph-like
ALL, respectively. Likewise, the 5-year overall survival rates for
patients with Ph-like ALL were inferior to those of patients with
non–Ph-like ALL in young adults (25.4% [95% CI, 14.8% to
37.5%] v 64.2% [95% CI, 53.1% to 73.3%], respectively; P, .001)
and adults (27.0% [95% CI, 13.3% to 42.7%] v 44.9% [95% CI,
33.5% to 55.7%], respectively; P = .023), but the difference in
3-year survival rates in older adults was not signiﬁcant between the
two groups (13.5% [95% CI, 2.3% to 34.3%] v 37.9% [95% CI,
19.2% to 56.6%], respectively; P = .64; Data Supplement). The lack
of signiﬁcance in older adults may be a result of the small number
of patients available for outcome analysis (n = 44); therefore,
Table 2. Clinical Characteristics of Patients by Genomic Subtype
Characteristic
BCR-ABL1
(n = 185) Ph-Like* (n = 194) MLL† (n = 123)
B-Cell Other
(n = 296) P
Median age, years (range) 47 (21-84) 40 (21-86) 43 (21-86) 41 (21-80)
Median WBC, 3 109/L (range) 58.0 (0.7-658) 56.6 (0.2-434) 119.8 (0.5-670) 26.8 (0.4-600) , .001
WBC, % , .001
, 50 3 109/L 64.4 66.7 34.6 89.0
$ 50 3 109/L 35.6 33.3 65.4 11.0
Sex, No. (%) .0094
Male 89 (48.1) 119 (61.3) 44 (35.8) 148 (50.0)
Female 96 (51.9) 73 (37.6) 78 (63.4) 148 (50.0)
NOTE. B-cell other includes ETV6-RUNX1, TCF3-PBX1, DUX4/ERG, and remaining pre-B ALL. WBC count comparison by Kruskal-Wallis rank sum test. Sex comparison
by Fisher’s exact test between Ph-like and B-other B-ALL.
Abbreviations: B-ALL, B-cell acute lymphoblastic leukemia; Ph-like, Philadelphia chromosome–like.
*Two patients with unknown sex status.
†One patient with unknown sex status.
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screening larger cohorts of patients older than age 60 years will
be important to assess the outcome of Ph-like ALL in the
elderly.
Genomic Landscape of Ph-Like ALL in Adults
Genomic alterations activating kinase signaling were identi-
ﬁed in 171 (88.1%) of 194 patients with Ph-like ALL and 171
(95.0%) of 180 patients with materials enabling genomic analysis.
Overall, 99 (51%) of 194 patients with Ph-like ALL had high
CRLF2 expression. The frequency was 51.1% in young adults,
46.8% in adults, and 58.4% in older adults. We identiﬁed IGH-
CRLF2 (n = 57; 57.6%) and P2RY8-CRLF2 (n = 21; 21.2%)
rearrangements; for 21 patients, there was insufﬁcient material for
analysis. Concomitant Janus kinase (JAK1/JAK2) mutations were
identiﬁed in 25 (25%) of 99 patients with high CRLF2 expression
(Data Supplement).
Transcriptome sequencing was performed in 86 of the
remaining 95 patients with Ph-like ALL. Genetic alterations were
classiﬁed into subgroups of kinase and cytokine receptor signaling
pathways (Fig 3). These included rearrangements of CRLF2 (51%
of patients), ABL class fusions (ABL1, ABL2, CSF1R, PDGFRA,
and PDGFRB; 9.8%), JAK2 (7.2%), or EPOR (5.2%); sequence
mutations of IL7R, SH2B3, JAK1, or JAK3 and rearrangement of
TYK2 (termed other JAK-STAT; 7.2%); Ras pathway mutations
(KRAS, NF1, PTPN11, and CBL1; 3.6%); and uncommon fusions
(FLT3, NTRK3, BLNK, and PTK2B; 4.1%). A subset of patients
did not have a kinase-activating alteration identiﬁed by tran-
scriptome analysis (4.6%) or lacked material for genomic analysis
(7.2%).
Rearrangements activating kinase signaling were identiﬁed in
126 (65%) of 194 patients, including 32 different rearrangements
(10 of which were recurrent) in the following 14 kinase or cytokine
receptor genes (Table 3; Data Supplement): JAK2 (eight fusion
partners),ABL1 (n = 5),ABL2 (n = 3), EPOR (n = 3),CRLF2 (n = 2),
PDGFRB (n = 2), TYK2 (n = 2), BLNK (n = 1), CBL (n = 1), CSF1R
(n = 1), FLT3 (n = 1),NTRK3 (n = 1), PDGFRA (n = 1), and PTK2B
(n = 1). The following 11 rearrangements had not previously been
identiﬁed in B-ALL: FIP1L1-PDGFRA, SNX29-PDGFRB, SMU1-
JAK2, ZNF340-JAK2, THADA-EPOR, SMARCA4-TYK2, ZNF340-
TYK2,ZYMM2-FLT3,DNTT-BLNK,TMEM2-PTK2B, andKANK1-
CBL1. All kinase fusions retained an intact tyrosine kinase domain
(Data Supplement) and showed increased expression of the kinase
gene downstream of the exon breakpoint (Data Supplement). With
the exception of EPOR rearrangements, we did not observe sig-
niﬁcant differences in the frequency of kinase subtypes across the age
groups (Data Supplement).
Sequence mutations in genes activating JAK-STAT signaling
were identiﬁed in 14 patients with low CRLF2 expression, in-
cluding IL7R (seven patients), JAK1 (two patients), JAK3 (one
patient), and SH2B3 (two patients) and two patients with rear-
rangements involving TYK2. Seven patients harbored alterations
within the Ras pathway only, including sequence mutations in
KRAS (ﬁve patients) and PTPN11 (one patient) and one patient
with a novel rearrangement involving CBL. In addition, two pa-
tients with KRAS mutations also harbored sequence mutations
within NF1 (Data Supplement).
Patients with Ph-like ALL were classiﬁed on the basis of an
LDA coefﬁcient between 0.5 and 1.24 Within this classiﬁcation, we
observed differences between the distribution of kinase groups on
the basis of the coefﬁcient. For patients with Ph-like ALL with
a rearrangement involving ABL class genes, CRLF2, or JAK2/EPOR,
we observed 90%, 68%, and 79% of patients, respectively, with
a coefﬁcient between 0.9 and 1. In contrast, 41% of patients with
other kinase or JAK-STAT alterations exhibited a coefﬁcient be-
tween 0.9 and 1. Patients harboring Ras pathway alterations had
a weaker coefﬁcient, with 86% of patients classiﬁed in the 0.5 to
0.74 category (Data Supplement). Altogether, patients harboring
a kinase rearrangement were more likely to have a coefﬁcient
greater than 0.9 than patients with a sequence mutation (73% v
31%, respectively; P, .001). Patients harboring rearrangements of
CRLF2 or JAK2/EPOR had a trend toward inferior 5-year event-
free and overall survival compared with patients harboring ABL
class or other JAK-STAT alterations (P = .057 and P = .072, re-
spectively; Data Supplement).
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Fig 1. Overall outcome of adult acute lymphoblastic leukemia. Kaplan-Meier
estimates of (A) event-free survival and (B) overall survival of young adults, adults,
and older adults combined. Outcome data were available for 582 of 798 patients
studied.
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Analysis of DNA copy number alterations conﬁrmed a high
frequency of IKZF1 alterations (deletion and mutation) in patients
with Ph-like ALL (120 of 165 patients; 73%). IKZF1 alterations
were also more common in patients with a kinase or cytokine
receptor rearrangement (109 of 137 patients; 80%) than a sequence
mutation (eight of 17 patients; 47%; P , .001). Other common
targets of genetic alteration included CDKN2A/B (51%), PAX5
(38%), BTG1 (33%), and EBF1 (22%; Data Supplement). We also
observed enrichment of copy number alterations of IKZF1, PAX5,
EBF1, and CDKN2A/B in patients harboring a Ph-like coefﬁcient
greater than 0.9 (Data Supplement). A summary of all copy
number alterations identiﬁed in Ph-like ALL is provided in the
Data Supplement. Overall, 142 (86%) of 165 patients with Ph-like
ALL assessed by SNP proﬁling harbored alterations affecting
lymphoid development (IKZF1, PAX5, EBF1, ETV6, and RUNX1),
and 89 (54%) of 165 patients had alterations of the cell cycle
(CDKN2A/B, TP53, and RB1).
DISCUSSION
In this comprehensive retrospective study of 798 patients with
B-ALL age 21 to 86 years, we have demonstrated that the frequency
of Ph-like ALL exceeds 20% across the adult age spectrum. With
the combined analysis of patients treated on different protocols,
Ph-like ALL is independently associated with a poor prognosis. We
show that Ph-like ALL in adults is characterized by a variety of
genetic alterations that activate kinase or cytokine receptor sig-
naling and that the majority of lesions are targetable with US Food
and Drug Administration–approved TKIs.
A similar spectrum of kinase-activating alterations was
identiﬁed in adults with Ph-like ALL as that found in children. The
overall frequency of CRLF2 rearrangement (51%) is similar to that
identiﬁed in previous reports, with older adults showing the
highest frequency at 58%. However, we observed a 25% frequency
of JAK mutations in CRLF2-rearranged adult patients, which is
lower than the frequency reported for childhood ALL (50%).8
Additional targets of mutation in CRLF2-rearranged patients in-
clude IL7R, FLT3, and SH2B3.8 Identiﬁcation of the other co-
operating lesions in adult patients will provide important insights
into the mechanisms of oncogenic signaling by CRLF2 in ALL.
We also show a high frequency of JAK2 and EPOR rear-
rangements in the adult ALL population. Overall, approximately
70% of adult patients with Ph-like ALL harbor genetic alterations
that may be targetable with JAK inhibitors, such as ruxolitinib.
These include CRLF2 rearrangements with or without JAK1/JAK2
mutation, rearrangements involving JAK2 and EPOR, and se-
quence mutations of JAK1, JAK3, IL7R, and SH2B3. The only
exception is TYK2, which is not sensitive to ruxolitinib and will
require development of selective TYK2 inhibitors.32 Multiple
studies have demonstrated potent activity of ruxolitinib in pre-
clinical models of Ph-like ALL or early T-cell precursor ALL.
Although variations in response were observed in CRLF2-rear-
ranged cells, this was independent of JAKmutation12,33 and is likely
a result of the presence of other genetic alterations activating JAK-
STAT signaling (eg, IL7R mutations).8 These preclinical studies
have shown that the efﬁcacy of ruxolitinib is determined by the
degree of JAK-STAT activation rather than JAK mutational status.
To determine the efﬁcacy of JAK inhibition in patients harboring
lesions activating the JAK-STAT pathway, ruxolitinib in combi-
nation with conventional chemotherapy will be assessed in trials
from the Children’s Oncology Group and The University of Texas
MD Anderson Cancer Center.
Another major Ph-like ALL genetic subgroup involves kinases
that are targeted by ABL inhibitors (imatinib and dasatinib), in-
cluding ABL1, ABL2, CSF1R, PDGFRA, and PDFGRB. Rear-
rangements resulting in FIP1L1-PDGFRA have been identiﬁed in
eosinophilic leukemia and are responsive to ABL inhibitors.31 We
report this fusion for the ﬁrst time, to our knowledge, in Ph-like
ALL. An additional new target of rearrangement is B-cell linker
(BLNK), an adaptor protein that transduces signals from the B-cell
receptor and activates the Ras pathway via ERK.34 Another pu-
tative mechanism of Ras activation was identiﬁed through the
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KANK1-CBL fusion. CBL is a negative regulator of signal trans-
duction pathways, including Ras. Fusion with KANK1 likely in-
activates CBL by disrupting the open reading frame, leading to
hyperactivation of Ras signaling. Overall, we identiﬁed 11 new
rearrangements that had not previously been identiﬁed in Ph-like
ALL. These data further highlight the genetic heterogeneity of Ph-
like ALL and the importance of incorporating comprehensive
sequencing to identify all genetic alterations.
To enable prompt delivery of TKIs, accurate and fast diagnosis
of patients with Ph-like ALL is a critical factor when designing
clinical trials for TKI therapy. In the research setting, we identiﬁed
patients with the Ph-like ALL signature using a TaqMan LDA card,
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Fig 3. Kinase alterations identiﬁed in patients with Philadelphia chromosome (Ph) –like acute lymphoblastic leukemia (ALL). Data are shown for 86 patients with Ph-like
ALL who underwent transcriptome sequencing. The cohort is divided into patients with ABL class fusions (ABL1, ABL2, CSF1R, PDGFRA, and PDGFRB); EPOR or JAK2
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Table 3. Kinase Fusions Identiﬁed in Philadelphia Chromosome–Like Acute Lymphoblastic Leukemia
Kinase Tyrosine Kinase Inhibitor No. of Partners No. of Patients 59 Genes
ABL1 Dasatinib 5 6 ETV6,8 NUP214,8 RCSD1,8 SNX2,8 SFPQ29
ABL2 Dasatinib 3 7 PAG1,8 RCSD1,8 ZC3HAV18
CSF1R Dasatinib 1 1 MEF2D30
PDGFRA Dasatinib 1 1 FIP1L131
PDGFRB Dasatinib 2 4 EBF1,8 SNX29
CRLF2 JAK2 inhibitor 2 99 IGH,8 P2RY88
JAK2 JAK2 inhibitor 8 14 ATF7IP,8 BCR,8 ETV6,8 PAX5,8 PPFIBP1,8 SMU1, SSBP2,8
ZNF340
EPOR JAK2 inhibitor 3 10 IGH,8 IGK,8 THADA
TYK2 TYK2 inhibitor 2 2 SMARCA4, ZNF340
FLT3 FLT3 inhibitor 1 1 ZMYM2
NTRK3 NTRK inhibitor 1 1 ETV68
PTK2B FAK inhibitor 1 1 TMEM2
BLNK 1 1 DNTT
CBL 1 1 KANK1
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which is rapidly performed in a Clinical Laboratory Improvement
Amendments–compliant laboratory. This is only a screening tool,
and additional approaches are required for the identiﬁcation of
speciﬁc kinase alterations. FISH was performed on patients with
high CRLF2 expression to identify CRLF2 rearrangements, and
RNA-seq was performed on the remainder of patients to identify
additional kinase alterations. Although effective for research studies,
this tiered approach may delay identiﬁcation of the kinase-activating
lesions in the diagnostic setting. A number of approaches are being
evaluated for the clinical identiﬁcation of Ph-like ALL and un-
derlying kinase-activating alterations. As a result of the genetic
complexity of Ph-like ALL, assays to identify rearrangements that are
agnostic of the 59 fusion partner are ideal. A simple and cost-effective
approach is to perform FISH for break apart of the kinase gene, which
will identify most fusions involving key kinase genes.9 Reverse tran-
scriptase PCR may be used as a screening or conﬁrmatory approach
but will only conﬁrm known fusions. Another option is the digital
molecular barcoding platform NanoString (NanoString, Seattle, WA),
which can multiplex more than 200 different genetic alterations. This
assay is simple and requires little material but also only identiﬁes
known fusions. Capture-based RNA sequencing (eg, Archer Fusion-
Plex Oncology Research Kit, Archer DX, Boulder, CO; Foundation
One Heme, Foundation Medicine, Cambridge, MA35) effectively
identiﬁes kinase fusions and is agnostic of the 59 fusion partner but
requires Clinical Laboratory Improvement Amendments–approved
sequencing capability. Thus, although FISH or targeted approaches are
satisfactory for a subset of alterations, it is likely that next-generation
sequencing technologies in diagnostic laboratories are required for the
comprehensive and timely identiﬁcation of patients with Ph-like ALL.
Although these assays may not be feasible for all clinical laboratories at
present, they will be increasingly available in the future.
In summary, Ph-like ALL is common across the age spectrum
of adult ALL, includingmore than 20%of patients age 21 to 86 years,
with a notably high prevalence of JAK-STAT activating alterations.
These ﬁndings warrant the development of clinical trials in adults
that assess the efﬁcacy of TKIs, similar to those that are being
established for pediatric ALL.
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Fig A1. CONSORT diagram. Among the 909 eligible patients with B-cell acute
lymphoblastic leukemia (B-ALL), 798 had adequate samples to screen for the
Philadelphia chromosome (Ph) –like ALL signature.
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